1-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone | 1393913-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone
• 英文别名: 1-[5-(2-hydroxy-2-pyridin-4-ylethyl)-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-8-yl]ethanone
• CAS: 1393913-51-3
• 化学式: C₂₁H₂₃N₃O₂
• 分子量: 349.433
• InChiKey: KVADBARVNNMCTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 2-[8-(1-hydroxyethyl)-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]-1-pyridin-4-ylethanol
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION

  摘要：

  氢化吡啶并[4,3-b]吲哚，吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚被描述。这些化合物可能与肾上腺素受体α2B结合并拮抗。这些化合物也可能与肾上腺素受体α1B结合并拮抗。这些化合物可能在治疗中发挥作用，例如（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可用于治疗对降低血压有反应或预期会有反应的疾病或症状。特别描述了使用这些化合物治疗心血管和肾脏疾病。

  公开号：

  US20150266884A1
• 作为产物：
  描述：

  1-(2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone 、 4-(oxiran-2-yl)pyridine 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.17h， 以6 mg的产率得到1-(2,3,4,5-tetrahydro-5-(2-hydroxy-2-(pyridin-4-yl)ethyl)-2-methyl-1H-pyrido[4,3-b]indol-8-yl)ethanone
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION

  摘要：

  氢化吡啶并[4,3-b]吲哚，吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚被描述。这些化合物可能与肾上腺素受体α2B结合并拮抗。这些化合物也可能与肾上腺素受体α1B结合并拮抗。这些化合物可能在治疗中发挥作用，例如（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可用于治疗对降低血压有反应或预期会有反应的疾病或症状。特别描述了使用这些化合物治疗心血管和肾脏疾病。

  公开号：

  US20150266884A1

文献信息

• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20130053367A1

  公开（公告）日：2013-02-28

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α 2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  本文描述了氢化吡啶并[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素受体α2A。这些化合物也可以结合并拮抗肾上腺素受体α2B；或这些化合物不是肾上腺素受体α2B的拮抗剂，并且这些化合物与第二个降低或预计降低个体血压的药物一起使用。这些化合物可以用于治疗，例如，调节血糖水平、增加胰岛素分泌和治疗对增加胰岛素产生有反应或预计会有反应的疾病或病况。特别描述了使用这些化合物治疗2型糖尿病的用途。
• COMPOUNDS AND METHODS FOR TREATING DIABETES
  申请人：Medivation Technologies, Inc

  公开号：US20130190294A1

  公开（公告）日：2013-07-25

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α 2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  本文描述了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素α2A受体。这些化合物也可以结合并拮抗肾上腺素α2B受体；或者这些化合物不是肾上腺素α2B受体的拮抗剂，并且这些化合物与第二种降低或预计降低个体血压的药物一起使用。这些化合物可以在治疗中发挥作用，例如，调节血糖水平、增加胰岛素分泌并治疗对增加胰岛素产生反应的疾病或情况。本文特别描述了使用这些化合物治疗2型糖尿病的方法。
• Compounds and methods for treatment of hypertension
  申请人：Protter Andrew Asher

  公开号：US08791132B2

  公开（公告）日：2014-07-29

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文介绍了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以与肾上腺素受体α2B结合并作为拮抗剂。这些化合物也可以与肾上腺素受体α1B结合并产生拮抗作用。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠的重吸收。这些化合物还可以用于治疗预计对降低血压有反应的疾病或病况。特别地，本文描述了这些化合物用于治疗心血管和肾脏疾病。
• Compounds and methods of treating diabetes
  申请人：Protter Andrew Asher

  公开号：US08815843B2

  公开（公告）日：2014-08-26

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B; or the compounds are not antagonists of the adrenergic receptor α2B and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  本文描述了氢化吡啶并[4,3-b]吲哚、吡啶并[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可能与肾上腺素受体α2A结合并具有拮抗作用。这些化合物还可能与肾上腺素受体α2B结合并具有拮抗作用；或这些化合物不是肾上腺素受体α2B的拮抗剂，并且这些化合物与第二个降低或预计降低个体血压的药物一起使用。这些化合物可能在治疗中发挥作用，例如，调节血糖水平，增加胰岛素分泌，并治疗对胰岛素产生增加反应的疾病或病况。特别描述了使用这些化合物治疗2型糖尿病的方法。
• US8791132B2
  申请人：——

  公开号：US8791132B2

  公开（公告）日：2014-07-29